ReviewNutrients2021
Phosphate, Microbiota and CKD.
Review in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Gut microbiota-targeted therapies in pediatric chronic kidney disease: gaps and opportunities.Pediatric nephrology (Berlin, Germany) · 2026Review
- Effects of High-Inorganic-Phosphorus Diet on Intestinal Mucosal Injury and Immune Alteration in Mice.Nutrients · 2026Article
- Nutritional Modulation of the Gut-Kidney Axis.Nutrients · 2026Review
- Association of live microbes intake and risk of all-cause, cardiovascular disease, and cancer-related mortality in patients with chronic kidney disease.Renal failure · 2025Article
- Correlation of gut microbiota metabolite trimethylamine N-oxide with inflammatory levels and osteoporosis in patients with diabetic nephropathy.World journal of diabetes · 2025Article
- Biomimetic wrinkled prebiotic microspheres with enhanced intestinal retention for hyperphosphatemia and vascular calcification.Science advances · 2025Article
- Investigation of the human-gut-kidney axis by fecal proteomics, highlights molecular mechanisms affected in CKD.Heliyon · 2024Article
- Dietary Phosphorus Levels Influence Protein-Derived Uremic Toxin Production in Nephrectomized Male Rats.Nutrients · 2024Article
- Characterization of gut microbiota in patients with stage 3-4 chronic kidney disease: a retrospective cohort study.International urology and nephrology · 2024Article
- Hyperparathyroidism, Serum Phosphorus and Dietary Intake in Hemodialysis Patients: Is There a Novel Relationship?International journal of molecular sciences · 2024Observational
- Effects of the novel sodium-dependent phosphate cotransporter 2b inhibitor DZ1462 on hyperphosphatemia in chronic kidney disease.American journal of translational research · 2024Article
- Uncovering specific taxonomic and functional alteration of gut microbiota in chronic kidney disease through 16S rRNA data.Frontiers in cellular and infection microbiology · 2024Article
- Association between dietary intake of selenium and chronic kidney disease in US adults: a cross-sectional study of NHANES 2015-2018.Frontiers in nutrition · 2024Article
- Inositol 1,4,5-trisphosphate receptor type 2 is associated with the bone-vessel axis in chronic kidney disease-mineral bone disorder.Renal failure · 2023Article
- Decreasing microbiota-derived uremic toxins to improve CKD outcomes.Clinical kidney journal · 2022Review
- Mineral and bone disorder and longterm survival in a chronic kidney disease grade 3b-4cohort.Renal failure · 2022Article
- Probiotics for kidney disease.Clinical kidney journal · 2022Article
- Applications of Metabolomics in Calcium Metabolism Disorders in Humans.International journal of molecular sciences · 2022Review
- Postbiotics and Kidney Disease.Toxins · 2022Review
- Solving the riddle of Aguascalientes nephropathy: nephron number, environmental toxins and family clustering.Clinical kidney journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Phosphate is a key uremic toxin associated with adverse outcomes. As chronic kidney disease (CKD) progresses, the kidney capacity to excrete excess dietary phosphate decreases, triggering compensatory endocrine responses that drive CKD-mineral and bone disorder (CKD-MBD). Eventually, hyperphosphatemia develops, and low phosphate diet and phosphate binders are prescribed. Recent data have identified a potential role of the gut microbiota in mineral bone disorders. Thus, parathyroid hormone (PTH) only caused bone loss in mice whose microbiota was enriched in the Th17 cell-inducing taxa segmented filamentous bacteria. Furthermore, the microbiota was required for PTH to stimulate bone formation and increase bone mass, and this was dependent on bacterial production of the short-chain fatty acid butyrate. We review current knowledge on the relationship between phosphate, microbiota and CKD-MBD. Topics include microbial bioactive compounds of special interest in CKD, the impact of dietary phosphate and phosphate binders on the gut microbiota, the modulation of CKD-MBD by the microbiota and the potential therapeutic use of microbiota to treat CKD-MBD through the clinical translation of concepts from other fields of science such as the optimization of phosphorus utilization and the use of phosphate-accumulating organisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.